Stay updated on Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial.
Sign up to get notified when there's something new on the Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial. page.

Latest updates to the Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial. page
- Check6 days agoChange DetectedThe web page has been updated to version 2.16.0, replacing the previous version 2.15.2.SummaryDifference0.1%
- Check13 days agoNo Change Detected
- Check20 days agoNo Change Detected
- Check34 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.0%
- Check41 days agoChange DetectedThe page has been updated to include new drug information related to breast cancer treatments, specifically mentioning Doxorubicin, Epirubicin, Cyclophosphamide, and endocrine therapy, while significant details about the study involving pembrolizumab have been removed.SummaryDifference15%
- Check56 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.0%
- Check63 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.0%
- Check92 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference0.5%
Stay in the know with updates to Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial.
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in ER+/HER2- Breast Cancer Clinical Trial. page.